Latest news
EMV Capital: AMR Bio targets FDA meeting to clear path for XF-73 Phase 3 trial - Proactive financial newsProactive financial news · Thu, 30 Jul 2026 09:05:00 GMTEMV Capital: ProAxsis eyes COPD market breakthrough with Imperial College London study - Proactive InvestorsProactive Investors · Wed, 29 Jul 2026 11:15:00 GMT